10x Genomics (TXG) awards 8,829 RSUs to board director

Rhea-AI Filing Summary

STUELPNAGEL JOHN R reported acquisition or exercise transactions in this Form 4 filing.

10x Genomics, Inc. director John R. Stuelpnagel received an equity award of 8,829 restricted stock units (RSUs), each representing one future share of Class A Common Stock upon vesting. The RSUs vest in four equal installments on each quarterly anniversary of May 21, 2026, as long as he continues as a service provider. After this grant, he holds 368,436 shares of Class A Common Stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider STUELPNAGEL JOHN R

Role null

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	8,829	$0.00	--

Holdings After Transaction: Class A Common Stock — 368,436 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 8,829 units Grant price per share: $0.00 per share Shares held after grant: 368,436 shares +1 more

4 metrics

RSUs granted 8,829 units Equity award to director on June 4, 2026

Grant price per share $0.00 per share Stated transaction price for RSU grant

Shares held after grant 368,436 shares Director’s Class A Common Stock holdings following transaction

RSU vesting start reference date May 21, 2026 Quarterly vesting anniversaries measured from this date

Key Terms

restricted stock units ("RSUs"), Class A Common Stock, service provider

3 terms

restricted stock units ("RSUs") financial

"Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Class A Common Stock financial

"Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

service provider financial

"subject to the Reporting Person continuing as a service provider through each such date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STUELPNAGEL JOHN R

(Last) (First) (Middle)

C/O 10X GENOMICS, INC.

6230 STONERIDGE MALL ROAD

(Street)

PLEASANTON CALIFORNIA 94588

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
10x Genomics, Inc. [ TXG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/04/2026		A		8,829(1)	A	$0	368,436	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting. 1/4th of the RSUs shall vest on each quarterly anniversary measured from May 21, 2026, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

Exhibit 24.1 - Power of Attorney

	/s/ Randy Wu, as Attorney-in-Fact for John R. Stuelpnagel	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did 10x Genomics (TXG) report for John R. Stuelpnagel?

10x Genomics reported that director John R. Stuelpnagel received a grant of 8,829 restricted stock units. Each RSU represents the right to receive one share of Class A Common Stock when it vests under the award’s schedule.

How many RSUs were granted to the 10x Genomics (TXG) director and at what price?

The director was granted 8,829 restricted stock units at a stated price of $0.00 per unit, indicating a compensation grant rather than an open-market purchase. Each RSU converts into one share of Class A Common Stock upon vesting.

What is the vesting schedule for the 8,829 RSUs granted by 10x Genomics (TXG)?

The 8,829 RSUs vest in four equal installments. One quarter of the RSUs vests on each quarterly anniversary measured from May 21, 2026, if the director continues as a service provider through each respective vesting date.

How many 10x Genomics (TXG) shares does John R. Stuelpnagel hold after this RSU grant?

Following the RSU grant, John R. Stuelpnagel is reported as holding 368,436 shares of 10x Genomics Class A Common Stock directly. This figure reflects his position after the 8,829-unit equity award discussed in the insider transaction.

Does the 10x Genomics (TXG) Form 4 show a buy or a sale of shares?

The Form 4 shows an acquisition through an equity award, not a market trade. The transaction is coded as a grant of 8,829 restricted stock units, rather than an open-market purchase or sale of existing Class A Common Stock shares.